药物性肝病患者髓过氧化物酶基因多态性分析

Analysis of Myeloperoxidase Gene Polymorphism in Patients with Drug-induced Liver Disease

目的探讨髓过氧化物酶(MPO)基因多态性与药物性肝病(DILI)之间的关系。方法病例采用对照分析的方法 ,方便收集37例药物性肝病患者和30例健康对照者外周血标本,提取DNA进行MPO-463G/A多态性检测。结果MP0-463 GG、GA和AA 3种基因型的频率在DILI组中分别为86.5%、10.8%和2.7%,在对照组中分别为73.4%、23.3%和3.3%;将携带MP0-463 GA和AA型者合并后与携带MPO-463 GG型相比较,患DILI的风险显著增高,相对于G等位基因,携带A等位基因的个体患DILI的风险显著降低,说明MP0-463 G/A多态性与DILI的发生有关。结论髓过氧化物酶基因多态性与药物性肝病易感性之间存在相关性,值得进一步研究。

Objective To discuss the correlation between the myeloperoxidase gene polymorphism and drug-induced liver disease. Methods The peripheral blood samples of 37 cases of patients with drug-induced liver disease and 30 healthy control people were collected according to the case control analysis method, and the MPO-463G/A polymorphism detection was carried out by extracting DNA. Results The genotype frequency of MP0-463 GG, GA and AA was respectively 86.5%,10.8% and 2.7% in the DILI group and 73.4%, 23.3% and 3.3% in the control group; the risk of suffering from DILI in patients with MP0-463 GA and AA obviously increased compared with that of the patients with MPO-463 GG, the risk of suffering from DILI of individuals with A allele obviously decreased compared with that of the individuals with G allele, which indicated that MP0-463 G/A polymorphism was correlated with the occurrence of the DILI. Conclusion Myeloperoxidase gene polymorphism has a correlation with the susceptibility of drug-induced liver disease, which is worth further research.